專技 - 藥物治療學題庫下載題庫

(A)(B) Carvedilol is a nonselective beta-adrenergic blocking agent with alpha-1 blocking activity

(C) carvedilol may improve hemodynamic and clinical function in patients with CONGESTIVE HEART FAILURE by the following mechanisms: protection from the cardiotoxic effects of increased catecholamines (ie, NOREPINEPHRINE); up-regulation of myocardial beta-1-adrenergic receptors (which improves myocardial responsiveness to beta-agonist stimulation); decrease in heart rate (which reduces myocardial oxygen consumption, enhances coronary artery blood flow, and improves myocardial perfusion); correct...

(A)(B) Carvedilol is a nonselective beta-adrenergic blocking agent with alpha-1 blocking activity

(C) carvedilol may improve hemodynamic and clinical function in patients with CONGESTIVE HEART FAILURE by the following mechanisms: protection from the cardiotoxic effects of increased catecholamines (ie, NOREPINEPHRINE); up-regulation of myocardial beta-1-adrenergic receptors (which improves myocardial responsiveness to beta-agonist stimulation); decrease in heart rate (which reduces myocardial oxygen consumption, enhances coronary artery blood flow, and improves myocardial perfusion); correction of abnormal intracellular calcium disposition; antioxidant effects ...

(D) The primary cytochrome P450 isoenzymes responsible for the metabolism of carvedilol are CYP2D6 and CYP2C9 and to a lesser extent CYP3A4, 2C19, 1A2, and 2E1.

Ref: Micromedex